DRIO - ラボスタイル・イノベ―ションズ （DarioHealth Corp.） ラボスタイル・イノベ―ションズDRIOのチャート
DRIOの企業情報
| symbol | DRIO |
|---|---|
| 会社名 | LabStyle Innovations Corp （ラボスタイル・イノベ―ションズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 ダリオ・ヘルス(DarioHealth Corp)（旧名：Labstyle Innovations Corp）はデジタル・ヘルス会社である。同社は、顧客にスマートフォンなどのモバイル機器を用する実験室テスト機能を有する技術の開発・商業化に従事する。同社の製品Dario Smart Diabetes Management Solution(Dario)は、ポケット・サイズ、血糖監視装置及びダリオスマートメーターと連合するソフトウェア・アプリケーションをベースするモバイル、リアルタイム、クラウドベース、糖尿病管理ソリューションである。 ラボスタイル・イノベ―ションズはイスラエルのデジタル・ヘルス・アプリ企業。モバイルで健康状態を検査するアプリの開発・商業化に従事する。糖尿病のためのアプリ「Dario」は、ランセット装置に特有の使い捨てテストカ―トリッジを利用、スマ―トフォンなどで血糖値を測定することが可能。血糖値の自己モニタリングとクラウドベ―スのサ―ビスを結合する。 DarioHealth Corp. is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the Company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Its cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario™mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. |
| 本社所在地 | 9 Halamish Street Caesarea Industrial Park 3088900 ISR |
| 代表者氏名 | Yoav Shaked Yoav Shaked |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +972 3-622-2929 |
| 設立年月日 | 40756 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 21人 |
| url | http://mydario.com |
| nasdaq_url | https://www.nasdaq.com/symbol/drio |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -14.50800 |
| 終値（lastsale） | 0.93 |
| 時価総額（marketcap） | 19847679.63 |
| 時価総額 | 時価総額（百万ドル） 19.84768 |
| 売上高 | 売上高（百万ドル） 6.76800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 14.65468 |
| 当期純利益 | 当期純利益（百万ドル） -24.40300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 DarioHealth Corp revenues increased 72% to $3.8M. Net loss applicable to common stockholders increased from $845K to $9.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Revaluation of warrants decrease of 100% to $1K (income) General and administrative increase of 22% to $3.8M (expense). |
DRIOのテクニカル分析
DRIOのニュース
DarioHealth Announces Two New Employer Contracts 2022/09/20 12:00:00 Benzinga
New accounts demonstrate continued demand for integrated and holistic digital chronic condition management solutions NEW YORK , Sept. 20, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO ) (the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today two new employer contracts, including one for the full suite of integrated solutions. The new accounts are scheduled to launch in late 2022 and early 2023. Through the first contract, Dario will deliver its full suite of integrated solutions to a leading global manufacturer. The second contract is for Dario''s behavioral health solution with an integrated Employee Assistance Program (EAP). This contract originated through an existing employer channel partnership and demonstrates the value of Dario''s recently announced strategic relationships in the market. The new multi-chronic account also reflects the growing demand for Dario''s integrated, holistic digital health solutions to address commonly co-occurring chronic conditions.
Looking Into DarioHealth''s Return On Capital Employed 2022/09/09 14:18:38 Benzinga
Benzinga Pro data, DarioHealth (NASDAQ: DRIO ) reported Q2 sales of $6.18 million. Earnings fell to a loss of $18.03 million, resulting in a 13.27% decrease from last quarter. DarioHealth collected $8.06 million in revenue during Q1, but reported earnings showed a $15.92 million loss. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com
Can you now get a good deal on DarioHealth Corp.’s shares? 2022/09/05 17:32:00 US Post News
In Friday’s session, DarioHealth Corp. (NASDAQ:DRIO) marked $4.45 per share, down from $4.58 in the previous session. While DarioHealth Corp. has underperformed by -2.84%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DRIO fell by -68.12%, with highs and lows ranging from $19.39 to $4.11, whereas […]
DarioHealth Corp. (NASDAQ: DRIO) Stock Has Dropped -24.73% Over The Month – Is There Room For Growth? 2022/08/20 13:00:00 Marketing Sentinel
DarioHealth Corp. (NASDAQ:DRIO)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 1.23. At the close of trading, the stock’s price was $4.90, to imply a decrease of -4.11% or -$0.21 in intraday trading. The DRIO share’s 52-week high remains $19.39, putting it -295.71% down since that peak … DarioHealth Corp. (NASDAQ: DRIO) Stock Has Dropped -24.73% Over The Month – Is There Room For Growth? Read More »
DarioHealth Corp. PT Lowered to $11 at Stifel 2022/08/16 12:09:17 Investing.com
https://www.investing.com/news/pro/dariohealth-corp-pt-lowered-to-11-at-stifel-432SI-2873693
DarioHealth gains 11% as new studies highlight benefits of diabetes solution 2022/06/03 18:04:59 Seeking Alpha
DarioHealth (DRI) a digital therapeutics company focused on chronic condition added over 11% on Friday in reaction to results from three new studies highlighting the benefits of…
DarioHealth Presents Three New Studies Demonstrating Improved Health in Users with Multiple Conditions at the American Diabetes Association''s 82nd Scientific Sessions 2022/06/03 12:00:00 PR Newswire
The studies demonstrated significant improvement in glucose control and reductions in blood pressure for users managing diabetes and hypertension and improvement in clinical measures for users with diabetes, stress and depression. The third study demonstrates that the Dario solution has…
DarioHealth bags two commercial contracts for digital therapeutic solutions 2022/05/19 13:52:07 Seeking Alpha
DarioHealth (DRIO) said on Thursday it had bagged two new contracts to provide digital therapeutics solutions to a national employer and a provider, both of which are expected to…
Benzinga''s Top Ratings Upgrades, Downgrades For May 13, 2022 2022/05/13 14:01:42 Benzinga
Upgrades B of A Securities upgraded the previous rating for Ritchie Bros Auctioneers Inc (NYSE: RBA ) from Underperform to Neutral. In the first quarter, Ritchie Bros Auctioneers showed an EPS of $0.46, compared to $0.25 from the year-ago quarter. The current stock performance of Ritchie Bros Auctioneers shows a 52-week-high of $76.17 and a 52-week-low of $48.65. Moreover, at the end of the last trading period, the closing price was at $58.91. For Ford Motor Co (NYSE: F ), Morgan Stanley upgraded the previous rating of Underweight to Equal-Weight. For the first quarter, Ford Motor had an EPS of $0.38, compared to year-ago quarter EPS of $0.89. The current stock performance of Ford Motor shows a 52-week-high of $25.87 and a 52-week-low of $11.28. Moreover, at the end of the last trading period, the closing price was at $12.44. For PaySign Inc (NASDAQ: PAYS ), Barrington Research upgraded the previous rating of Market Perform to Outperform. For the first quarter, PaySign had an EPS of $0.01, compared to year-ago quarter EPS of $0.03.
DarioHealth Corp. (DRIO) CEO Erez Raphael on Q1 2022 Results - Earnings Call Transcript 2022/05/12 17:35:05 Seeking Alpha
DarioHealth Corp. (NASDAQ:NASDAQ:DRIO) Q1 2022 Earnings Conference Call May 12, 2022 08:30 AM ET Company Participants Glenn Garmont - Investor Relations Erez Raphael - Chief Executive…
Lasso Accelerates Client Expansion Across All Major Healthcare Verticals 2022/04/13 11:32:00 Kwhen Finance
DarioHealth reports Q4 results 2022/03/23 04:52:15 Seeking Alpha
DarioHealth press release (DRIO): Q4 pro-forma gross profit was $1.33M, or 22.1% of revenues, for the three months ended December 31, 2021.Revenue of $6.03M (+189.9% Y/Y).Non-GAAP…
Recap: DarioHealth Q4 Earnings 2022/03/22 11:36:44 Benzinga
DarioHealth (NASDAQ: DRIO ) reported its Q4 earnings results on Tuesday, March 22, 2022 at 06:30 AM. Here''s what investors need to know about the announcement. Earnings DarioHealth missed estimated earnings by 2.83%, reporting an EPS of $-1.09 versus an … Full story available on Benzinga.com
DarioHealth GAAP EPS of -$4.07 beats by $0.65, revenue of $20.51M misses by $0.11M (NASDAQ:DRIO) 2022/03/22 10:41:33 Seeking Alpha
DarioHealth press release (DRIO): FY GAAP EPS of -$4.07 beats by $0.65.Revenue of $20.51M (+170.9% Y/Y) misses by $0.11M.Shares -0.77% PM.
DarioHealth Signs Multi-Year $30 Million-Dollar Deal With Sanofi U.S., Partnership To Increase Sales Reach In the Health Plan Market 2022/03/01 19:14:23 Benzinga
Image sourced from Pixabay This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. DarioHealth Corp. (NASDAQ: DRIO ) announced that it has entered into a strategic agreement with Sanofi U.S., an innovative global healthcare company. The multi-year, $30 million-dollar agreement, which is subject to certain contingencies, will help accelerate commercial adoption of Dario''s full suite of digital therapeutics and drive the expansion of digital health solutions on the Dario platform. Dario and Sanofi will collaborate on promoting the Dario multi-condition digital therapeutics solution, significantly increasing Dario''s sales reach in the health plan market and selectively in the employer channel. In addition, the agreement calls for Dario and Sanofi to develop new … Full story available on Benzinga.com